专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006057912A3 RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 审中-公开
标题翻译： RASAGILINE ORAZY DISINTEGRATING组合物
公开(公告)号：WO2006057912A3
公开(公告)日：2006-08-17
申请号：PCT/US2005041882
申请日：2005-11-17
申请人： TEVA PHARMA , TEVA PHARMA , PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/135
CPC分类号： A61K9/0056 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/135 , A61K31/4166
摘要： This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.
摘要翻译：本发明提供了包含雷沙吉兰或雷沙吉兰药学上可接受的盐的固体药物组合物，以及具有至少两种糖醇的非丝状微观结构的颗粒。本发明还提供了一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒，补充糖醇，辅助流药剂和补充崩解剂。本发明进一步提供了治疗患有帕金森氏病的受试者的方法，包括给予受试者治疗有效量的固体药物组合物，从而治疗受试者。最后，本发明提供了制备这种固体药物组合物的方法。

2. 发明专利

IL183236A Solid pharmaceutical composition of rasagiline 未知
公开(公告)号：IL183236A
公开(公告)日：2014-03-31
申请号：IL18323607
申请日：2007-05-15
申请人： TEVA PHARMA , GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT
发明人： GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT

3. 发明专利

IL195724A Stable laquinimod preparations 未知
公开(公告)号：IL195724A
公开(公告)日：2015-09-24
申请号：IL19572408
申请日：2008-12-04
申请人： TEVA PHARMA , LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
发明人： LICHT DANIELLA , PATASHNIK SHULAMIT , GILBERT ADRIAN
IPC分类号： A61K20060101 , A61P20060101
摘要： The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.

4. 发明申请

WO03005967A3 DUAL RELEASE LEVODOPA ETHYL ESTER AND DECARBOXYLASE IN CONTROLLED RELEASE CORE 审中-公开
标题翻译：控制释放核心中的双释放乙醇醚和脱羧酶
公开(公告)号：WO03005967A3
公开(公告)日：2003-09-04
申请号：PCT/US0222206
申请日：2002-07-12
申请人： TEVA PHARMA , TEVA PHARMA , LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
发明人： LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K31/198 , A61K45/06 , A61P25/16
CPC分类号： A61K45/06 , A61K9/2013 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K31/198 , A61K2300/00
摘要： A tablet which comprises: an inner core formulated for controlled release comprising a mixture of (a) a granulated admixture of a decarboxylase inhibitor and a surfactant, and (b) levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof; and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a granulated decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof. The subject invention also encompasses a method of treating patients suffering from Parkinson's disease or related disorders by the administration of the pharmaceutical compositions of the subject invention. Additionally, the subject invention provides methods of manufacturing the tablets of the subject invention.
摘要翻译：一种片剂，其包含：配制用于控释的内核，其包含（a）脱羧酶抑制剂和表面活性剂的颗粒状混合物的混合物，和（b）左旋多巴乙酯或其衍生物或药学上可接受的盐; 以及包封内核并配制成立即释放的外层，其包含粒状脱羧酶抑制剂和左旋多巴乙酯或其衍生物或药学上可接受的盐的混合物。本发明还包括通过施用本发明的药物组合物治疗患有帕金森病或相关病症的患者的方法。另外，本发明提供了制造本发明的片剂的方法。

5. 发明申请

WO03005968A2 DUAL RELEASE FORMULATION COMPRISING LEVODOPA ETHYL ESTER AND A DECARBOXYLASE INHIBITOR IN AN IMMEDIATE-RELEASE LAYER WITH LEVODOPAETHYL ESTER IN A CONTROLLED RELEASE CORE 审中-公开
标题翻译：在释放出的核心内含有左旋乙酸酯的立即释放层中的双酚A乙酯和脱羧酶抑制剂的双重释放配方
公开(公告)号：WO03005968A2
公开(公告)日：2003-01-23
申请号：PCT/US0222207
申请日：2002-07-12
申请人： TEVA PHARMA , TEVA PHARMA , LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
发明人： LICHT DANIELA , PATASHNIK SHULAMIT , NAFTALI EZMIRA , SAYAG NAIM , GILBERT ADRIAN , COHEN SASSON , ZOLLMANN CORINNE
IPC分类号： A61K9/20 , A61K9/22 , A61K9/24 , A61K9/26 , A61K31/198 , A61K45/06 , A61P25/16 , A61K
CPC分类号： A61K45/06 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/209 , A61K31/198 , A61K2300/00
摘要： A tablet which comprises an inner core formulated for controlled release consisting essentially of a mixture of levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, a carrier and an inner core excipient; and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof. The subject invention also encompasses a method of treating patients suffering from Parkinson's disease or related disorders by the administration of the pharmaceutical compositions of the subject invention. The subject invention also provides methods of manufacturing the tablets of the subject invention.
摘要翻译：一种片剂，其包含配制成用于控释的内核，其主要由左旋多巴乙酯或其衍生物或其药学上可接受的盐，载体和内核赋形剂的混合物组成; 以及封装内核并配制成立即释放的外层，其包含脱羧酶抑制剂和左旋多巴乙酯或其衍生物或药学上可接受的盐的混合物。本发明还包括通过施用本发明的药物组合物治疗患有帕金森病或相关病症的患者的方法。本发明还提供了制备本发明的片剂的方法。

6. 发明申请

WO2007146248A2 STABLE LAQUINIMOD PREPARATIONS 审中-公开
标题翻译：稳定的液体制剂
公开(公告)号：WO2007146248A2
公开(公告)日：2007-12-21
申请号：PCT/US2007013721
申请日：2007-06-12
申请人： TEVA PHARMA , TEVA PHARMA
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/4704
CPC分类号： A61K31/47 , A61K31/4704 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N- phenyl -1,2, -dihydro- 4 -hydroxy- 5 - chloro- 1 -methyl -2 - oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及一种药物组合物，其包含N-乙基-N-苯基-1,2， - 二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺的药学上可接受的盐，甲基葡糖胺和药学可接受的载体。

7. 发明申请

WO2006014973A2 PHARMACEUTICAL DOSAGE FORMS INCLUDING RASAGILINE 审中-公开
标题翻译：药物剂型包括雷沙吉兰
公开(公告)号：WO2006014973A2
公开(公告)日：2006-02-09
申请号：PCT/US2005026517
申请日：2005-07-26
申请人： TEVA PHARMA , TEVA PHARMA
发明人： LERNER E ITZHAK , ROSENBERGER VERED , AQUA OFER , FLASHNER-BARAK MOSHE , GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT
IPC分类号： A61K9/48 , A61K9/22
CPC分类号： A61K9/2072 , A61K9/2018 , A61K9/2081 , A61K9/2846 , A61K9/5026 , A61K9/5078
摘要： Provided are pharmaceutical dosage forms that include rasagiline formulated and fabricated so that release of rasagiline in the stomach is retarded or inhibited.
摘要翻译：提供药物剂型，其包括配制和制造的雷沙吉兰，使得雷沙吉兰在胃中的释放被延迟或抑制。

8. 发明公开

EP1827409A4 RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 有权
标题翻译： IN嘴巴崩解剂雷沙吉兰的组合物
公开(公告)号：EP1827409A4
公开(公告)日：2008-03-19
申请号：EP05851829
申请日：2005-11-17
申请人： TEVA PHARMA
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/135 , A61K47/26 , A61P25/16
CPC分类号： A61K9/0056 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K31/135 , A61K31/4166

9. 发明公开

EP1778196A4 PHARMACEUTICAL DOSAGE FORMS INCLUDING RASAGILINE 审中-公开
标题翻译：药物剂量随雷沙吉兰FORMS
公开(公告)号：EP1778196A4
公开(公告)日：2008-12-17
申请号：EP05782669
申请日：2005-07-26
申请人： TEVA PHARMA
发明人： LERNER E ITZHAK , ROSENBERGER VERED , AQUA OFER , FLASHNER-BARAK MOSHE , GILBERT ADRIAN , LICHT DANIELLA , PATASHNIK SHULAMIT
IPC分类号： A61K9/20 , A61K31/4439
CPC分类号： A61K9/2072 , A61K9/2018 , A61K9/2081 , A61K9/2846 , A61K9/5026 , A61K9/5078

10. 发明公开

EP2035001A4 STABLE LAQUINIMOD PREPARATIONS 有权转让
标题翻译：稳定的LAQUINIMOD制剂
公开(公告)号：EP2035001A4
公开(公告)日：2009-09-23
申请号：EP07809468
申请日：2007-06-12
申请人： TEVA PHARMA
发明人： PATASHNIK SHULAMIT , LICHT DANIELLA , GILBERT ADRIAN
IPC分类号： A61K31/47
CPC分类号： A61K31/47 , A61K31/4704 , A61K2300/00

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式